Arcus Biosciences, Inc.

NYSE:RCUS

13.41 (USD) • At close February 4, 2025
Bedrijfsnaam Arcus Biosciences, Inc.
Symbool RCUS
Munteenheid USD
Prijs 13.41
Beurswaarde 1,227,170,556
Dividendpercentage 0%
52-weken bereik 12.53 - 20.31
Industrie Biotechnology
Sector Healthcare
CEO Dr. Terry J. Rosen Ph.D.
Website https://www.arcusbio.com

An error occurred while fetching data.

Over Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The

Vergelijkbare Aandelen

Avanos Medical, Inc. logo

Avanos Medical, Inc.

AVNS

17.39 USD

Taro Pharmaceutical Industries Ltd. logo

Taro Pharmaceutical Industries Ltd.

TARO

42.975 USD

Paragon 28, Inc. logo

Paragon 28, Inc.

FNA

13 USD

U.S. Physical Therapy, Inc. logo

U.S. Physical Therapy, Inc.

USPH

88.6 USD

Cano Health, Inc. logo

Cano Health, Inc.

CANO

2.3 USD

Bright Health Group, Inc. logo

Bright Health Group, Inc.

BHG

16.35 USD

Nevro Corp. logo

Nevro Corp.

NVRO

5.13 USD

Brookdale Senior Living Inc. logo

Brookdale Senior Living Inc.

BKD

4.64 USD

Oscar Health, Inc. logo

Oscar Health, Inc.

OSCR

15.28 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)